Felisa Cilurzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1163049/publications.pdf Version: 2024-02-01



FELISA CILLIDZO

#	Article	IF	CITATIONS
1	Nanotechnology-based green and efficient alternatives for the management of plant diseases. , 2022, , 253-262.		0
2	Conventional Nanosized Drug Delivery Systems for Cancer Applications. Advances in Experimental Medicine and Biology, 2021, 1295, 3-27.	1.6	6
3	Tendon Tissue Repair in Prospective of Drug Delivery, Regenerative Medicines, and Innovative Bioscaffolds. Stem Cells International, 2021, 2021, 1-23.	2.5	14
4	Design, synthesis and characterization of a PEGylated stanozolol for potential therapeutic applications. International Journal of Pharmaceutics, 2020, 573, 118826.	5.2	3
5	Targeting of the Pilosebaceous Follicle by Liquid Crystal Nanocarriers: In Vitro and In Vivo Effects of the Entrapped Minoxidil. Pharmaceutics, 2020, 12, 1127.	4.5	22
6	Diameters and Fluorescence Calibration for Extracellular Vesicle Analyses by Flow Cytometry. International Journal of Molecular Sciences, 2020, 21, 7885.	4.1	35
7	Ammonium glycyrrhizate skin delivery from ultradeformable liposomes: A novel use as an anti-inflammatory agent in topical drug delivery. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111152.	5.0	49
8	Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study. MedChemComm, 2019, 10, 1892-1899.	3.4	3
9	Mathematical Models as Tools to Predict the Release Kinetic of Fluorescein from Lyotropic Colloidal Liquid Crystals. Materials, 2019, 12, 693.	2.9	49
10	Sclareol-loaded hyaluronan-coated PLGA nanoparticles: Physico-chemical properties and in vitro anticancer features. International Journal of Biological Macromolecules, 2019, 132, 550-557.	7.5	35
11	Polydocanol foam stabilized by liposomes: Supramolecular nanoconstructs for sclerotherapy. Colloids and Surfaces B: Biointerfaces, 2019, 175, 469-476.	5.0	7
12	Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1513-1522.	1.7	13
13	An insight of in vitro transport of PEGylated non-ionic surfactant vesicles (NSVs) across the intestinal polarized enterocyte monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 432-442.	4.3	16
14	Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography-diode array detector. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 192-199.	2.8	17
15	Innovative vesicles for dermal and transdermal drug delivery. , 2018, , 175-197.		1
16	Interaction between PEG lipid and DSPE/DSPC phospholipids: An insight of PEGylation degree and kinetics of de-PEGylation. Colloids and Surfaces B: Biointerfaces, 2017, 155, 266-275.	5.0	41
17	Physicochemical characterization of pH-responsive and fusogenic self-assembled non-phospholipid vesicles for a potential multiple targeting therapy. International Journal of Pharmaceutics, 2017, 528, 18-32.	5.2	23
18	Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Scientific Reports, 2015, 5, 17579.	3.3	110

Felisa Cilurzo

#	Article	IF	CITATIONS
19	Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert. Medicinal Chemistry, 2015, 11, 391-399.	1.5	8
20	Synthesis and physico-chemical characterization of a β-cyclodextrin conjugate for sustained release of Acyclovir. Carbohydrate Polymers, 2015, 131, 159-167.	10.2	15
21	Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 30-39.	4.3	71
22	Polyaspartamide-Doxorubicin Conjugate as Potential Prodrug for Anticancer Therapy. Pharmaceutical Research, 2015, 32, 1557-1569.	3.5	19
23	Influence of the Supramolecular Micro-Assembly of Multiple Emulsions on their Biopharmaceutical Features and <i>In vivo</i> Therapeutic Response. Current Drug Targets, 2015, 16, 1612-1622.	2.1	13
24	Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opinion on Drug Delivery, 2013, 10, 1653-1668.	5.0	65
25	Celecoxib-loaded PLGA/cyclodextrin microspheres: Characterization and evaluation of anti-inflammatory activity on human chondrocyte cultures. Colloids and Surfaces B: Biointerfaces, 2013, 111, 289-296.	5.0	28
26	Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S55-S60.	0.4	12
27	Nexavar®-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 86.	0.4	4
28	Annual report on adverse events related with vaccines use in Calabria (Italy): 2012. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S61-S65.	0.4	10
29	Liposomal chemotherapeutics. Future Oncology, 2013, 9, 1849-1859.	2.4	61
30	Paclitaxel-loaded ethosomes®: Potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 102-112.	4.3	100
31	Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. International Journal of Pharmaceutics, 2012, 422, 229-237.	5.2	80
32	Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles. Journal of Controlled Release, 2012, 162, 143-151.	9.9	70
33	Ethosomes® and transfersomes® containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomedical Microdevices, 2012, 14, 119-130.	2.8	83
34	Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. Journal of Research in Medical Sciences, 2012, 17, 872-5.	0.9	18
35	A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB. Neuroscience Letters, 2010, 469, 93-96.	2.1	10
36	Colloidal carriers for the enhanced delivery through the skin. Expert Opinion on Drug Delivery, 2008, 5, 737-755.	5.0	79

#	Article	IF	CITATIONS
37	Innovative Drug Delivery Systems for the Administration of Natural Compounds. Current Bioactive Compounds, 2007, 3, 262-277.	0.5	41